(September 5, 2019) OCRA funded investigator Dmitriy Zamarin, MD, PhD contributed to a study that provides an intriguing hypothesis that mutation in genes like SMARCA4 may improve tumor recognition by the immune system. The body’s immune system plays a major role in controlling tumor growth. Specialized immune cells called T-cells identify cancer cells as “foreign” … Continued
(August 22, 2019) This week, The US Preventive Services Task Force published new recommendations on risk assessment, genetic counseling, and genetic testing for BRCA mutations and BRCA-related cancers. The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases … Continued
(August 20, 2019) A new direction for research in ovarian cancer was brought to light last month thanks to a study published in Lancet Oncology. Researchers led by Dr. Nuno R. Nené of the University College London are investigating the role of microbiota in an individual’s risk of developing cancer. “The application of vaginal suppositories … Continued
(July 26, 2019) OCRA grantee Michael Yaffe, MD, PhD, led a study published earlier this month in Cell Systems which found success targeting cancer cells by combining two existing classes of drugs. Dr. Yaffe and colleagues found that this combination, which targets the cancer cells’ ability to divide, dramatically increases the drug’s capacity to kill … Continued
Couldn’t make it to our National Conference? Watch our expert presentations LIVE! For the first time, we live streamed all general sessions, so you can watch as our expert speakers present the latest ovarian cancer updates, from wherever you are. These broadcasts will remain available for viewing for a limited period of time following the original … Continued
(June 18, 2019) Results of new trials, funded in part by OCRA though the Ovarian Cancer Dream Team and published in JAMA Oncology, show that combination niraparib plus pembrolizumab therapy showed promising antitumor activity in patients with ovarian cancer. Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options … Continued
Four multidisciplinary teams to be funded to study survivorship (June 13, 2019) In a new collaboration, the American Cancer Society and Ovarian Cancer Research Alliance have joined forces to fund multidisciplinary research projects to explore new ways of detecting, treating, and preventing ovarian cancer relapse and for improving quality of life among those diagnosed with … Continued
OCRA is back from the American Society of Clinical Oncology’s annual meeting in Chicago, where doctors and researchers met to discuss the latest in the care of women with ovarian cancer. A few highlights: Progress is being made in the fight against ovarian cancer. Help keep research moving forward with your gift today.
(May 21, 2019) Earlier this month, Nature Genetics published a study, in part funded by OCRA, that found 34 genes were connected to women developing the earliest stages of ovarian cancer. Using data compiled by the Ovarian Cancer Association Consortium, researchers looked at the genetic profiles of around 25,000 women diagnosed with ovarian cancer and … Continued
(May 20, 2019) University of Chicago gynecologic oncologist Nita K. Lee wants the next generation of doctors to know that the story of ovarian cancer is changing for the better in small and meaningful ways. “I don’t want to sugarcoat this terrible disease, but I also want students to see that women are living longer,” … Continued
(April 3, 2019) In March, ovarian cancer researchers, clinicians and advocates gathered to attend the much-anticipated Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer, to discuss the latest cutting edge research. OCRA Research Advocate, Scientific Advisory Committee member, and ovarian cancer survivor Annie Ellis attended the meeting and wrote a report highlighting … Continued
(March 26, 2019) The NCCN, or the National Comprehensive Cancer Network, recently updated its clinical guidelines for the treatment of ovarian cancers. The guidelines, a summary of which can be found here, have been updated after several studies were completed and the FDA approved several new drugs. The new guidelines address topics such as PARP … Continued
Get email updates about research news, action alerts, and ways to join the fight.
